Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CARTITUDE-2: JNJ-68284528 in Multiple Myeloma
NCT04133636Phase 2Active, not recruiting
- Sponsor
- Janssen Pharmaceutical
- Start
- Nov 2019
- Primary completion
- Feb 2027
- Modality
- Gene Editing, Gene Silencing, CAR-T Cells
- Countries
- 8
01
Overview
Phase 2, open-label, single-arm trial of ciltacabtagene autoleucel in multiple myeloma (MM), sponsored by Janssen Pharmaceutical. Primary endpoints: Percentage of Participants with Negative Minimal Residual Disease (MRD) at 1 year and Percentage of Participants with Sustained MRD Negative Complete Response (CR) at 1 year. Started Nov 2019; status: active, not recruiting.
02
Drugs
ciltacabtagene autoleucel
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NCT04133636.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04133636.